Review Article | Published:

Skeletal muscle mitochondrial remodeling in exercise and diseases

Cell Researchvolume 28pages969980 (2018) | Download Citation

Abstract

Skeletal muscle fitness and plasticity is an important determinant of human health and disease. Mitochondria are essential for maintaining skeletal muscle energy homeostasis by adaptive re-programming to meet the demands imposed by a myriad of physiologic or pathophysiological stresses. Skeletal muscle mitochondrial dysfunction has been implicated in the pathogenesis of many diseases, including muscular dystrophy, atrophy, type 2 diabetes, and aging-related sarcopenia. Notably, exercise counteracts the effects of many chronic diseases on skeletal muscle mitochondrial function. Recent studies have revealed a finely tuned regulatory network that orchestrates skeletal muscle mitochondrial biogenesis and function in response to exercise and in disease states. In addition, increasing evidence suggests that mitochondria also serve to “communicate” with the nucleus and mediate adaptive genomic re-programming. Here we review the current state of knowledge relevant to the dynamic remodeling of skeletal muscle mitochondria in response to exercise and in disease states.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Glancy, B. et al. Mitochondrial reticulum for cellular energy distribution in muscle. Nature 523, 617–620 (2015).

  2. 2.

    Egan, B. & Zierath, J. R. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 17, 162–184 (2013).

  3. 3.

    Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650 (1990).

  4. 4.

    Gulick, T., Cresci, S., Caira, T., Moore, D. D. & Kelly, D. P. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl Acad. Sci. USA 91, 11012–11016 (1994).

  5. 5.

    Brandt, J. M., Djouadi, F. & Kelly, D. P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 273, 23786–23792 (1998).

  6. 6.

    van der Meer, D. L. et al. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res. 38, 2839–2850 (2010).

  7. 7.

    McMullen, P. D. et al. A map of the PPARalpha transcription regulatory network for primary human hepatocytes. Chem. Biol. Interact. 209, 14–24 (2014).

  8. 8.

    Cresci, S., Wright, L. D., Spratt, J. A., Briggs, F. N. & Kelly, D. P. Activation of a novel metabolic gene regulatory pathway by chronic stimulation of skeletal muscle. Am. J. Physiol. 270, C1413–C1420 (1996).

  9. 9.

    Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl Acad. Sci. USA 94, 4312–4317 (1997).

  10. 10.

    Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl Acad. Sci. USA 94, 4318–4323 (1997).

  11. 11.

    Krey, G. et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779–791 (1997).

  12. 12.

    Chakravarthy, M. V. et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138, 476–488 (2009).

  13. 13.

    Finck, B. N. et al. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 1, 133–144 (2005).

  14. 14.

    Gan, Z. et al. The nuclear receptor PPARbeta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 25, 2619–2630 (2011).

  15. 15.

    Muoio, D. M. et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J. Biol. Chem. 277, 26089–26097 (2002).

  16. 16.

    Burkart, E. M. et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117, 3930–3939 (2007).

  17. 17.

    Narkar, V. A. et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405–415 (2008).

  18. 18.

    Fan, W. et al. PPARdelta promotes running endurance by preserving glucose. Cell Metab. 25, 1186–1193.e1184 (2017).

  19. 19.

    Giguere, V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr. Rev. 29, 677–696 (2008).

  20. 20.

    Dufour, C. R. et al. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 5, 345–356 (2007).

  21. 21.

    Perry, M. C., Dufour, C. R., Tam, I. S., B’Chir, W. & Giguere, V. Estrogen-related receptor-alpha coordinates transcriptional programs essential for exercise tolerance and muscle fitness. Mol. Endocrinol. 28, 2060–2071 (2014).

  22. 22.

    Huss, J. M., Torra, I. P., Staels, B., Giguere, V. & Kelly, D. P. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24, 9079–9091 (2004).

  23. 23.

    LaBarge, S., McDonald, M., Smith-Powell, L., Auwerx, J. & Huss, J. M. Estrogen-related receptor-alpha (ERRalpha) deficiency in skeletal muscle impairs regeneration in response to injury. FASEB J. 28, 1082–1097 (2014).

  24. 24.

    Narkar, V. A. et al. Exercise and PGC-1alpha-independent synchronization of type I muscle metabolism and vasculature by ERRgamma. Cell Metab. 13, 283–293 (2011).

  25. 25.

    Rangwala, S. M. et al. Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity. J. Biol. Chem. 285, 22619–22629 (2010).

  26. 26.

    Gan, Z. et al. Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism. J. Clin. Invest. 123, 2564–2575 (2013).

  27. 27.

    van Rooij, E. et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell 17, 662–673 (2009).

  28. 28.

    Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839 (1998).

  29. 29.

    Puigserver, P. et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286, 1368–1371 (1999).

  30. 30.

    Vega, R. B., Huss, J. M. & Kelly, D. P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20, 1868–1876 (2000).

  31. 31.

    Huss, J. M., Kopp, R. P. & Kelly, D. P. Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J. Biol. Chem. 277, 40265–40274 (2002).

  32. 32.

    Pilegaard, H., Saltin, B. & Neufer, P. D. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J. Physiol. 546, 851–858 (2003).

  33. 33.

    Baar, K. et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 16, 1879–1886 (2002).

  34. 34.

    Terada, S., Kawanaka, K., Goto, M., Shimokawa, T. & Tabata, I. Effects of high-intensity intermittent swimming on PGC-1alpha protein expression in rat skeletal muscle. Acta Physiol. Scand. 184, 59–65 (2005).

  35. 35.

    Lin, J. et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797–801 (2002).

  36. 36.

    Rowe, G. C. et al. Disconnecting mitochondrial content from respiratory chain capacity in PGC-1-deficient skeletal muscle. Cell Rep. 3, 1449–1456 (2013).

  37. 37.

    Zechner, C. et al. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab. 12, 633–642 (2010).

  38. 38.

    Leick, L. et al. PGC-1alpha is not mandatory for exercise- and training-induced adaptive gene responses in mouse skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 294, E463–E474 (2008).

  39. 39.

    Ballmann, C., Tang, Y., Bush, Z. & Rowe, G. C. Adult expression of PGC-1alpha and -1beta in skeletal muscle is not required for endurance exercise-induced enhancement of exercise capacity. Am. J. Physiol. Endocrinol. Metab. 311, E928–e938 (2016).

  40. 40.

    Rowe, G. C., El-Khoury, R., Patten, I. S., Rustin, P. & Arany, Z. PGC-1alpha is dispensable for exercise-induced mitochondrial biogenesis in skeletal muscle. PLoS ONE 7, e41817 (2012).

  41. 41.

    Miura, S. et al. An increase in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to exercise is mediated by beta-adrenergic receptor activation. Endocrinology 148, 3441–3448 (2007).

  42. 42.

    Herzig, S. et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183 (2001).

  43. 43.

    Jager, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl Acad. Sci. USA 104, 12017–12022 (2007).

  44. 44.

    Canto, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056–1060 (2009).

  45. 45.

    Handschin, C., Rhee, J., Lin, J., Tarr, P. T. & Spiegelman, B. M. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc. Natl Acad. Sci. USA 100, 7111–7116 (2003).

  46. 46.

    Czubryt, M. P., McAnally, J., Fishman, G. I. & Olson, E. N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc. Natl Acad. Sci. USA 100, 1711–1716 (2003).

  47. 47.

    Daitoku, H., Yamagata, K., Matsuzaki, H., Hatta, M. & Fukamizu, A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52, 642–649 (2003).

  48. 48.

    Riehle, C. et al. Insulin receptor substrates are essential for the bioenergetic and hypertrophic response of the heart to exercise training. Mol. Cell. Biol. 34, 3450–3460 (2014).

  49. 49.

    Mootha, V. K. et al. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl Acad. Sci. USA 101, 6570–6575 (2004).

  50. 50.

    Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

  51. 51.

    Cho, Y., Hazen, B. C., Russell, A. P. & Kralli, A. Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1)- and estrogen-related receptor (ERR)-induced regulator in muscle 1 (Perm1) is a tissue-specific regulator of oxidative capacity in skeletal muscle cells. J. Biol. Chem. 288, 25207–25218 (2013).

  52. 52.

    Gray, S. et al. The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J. Biol. Chem. 277, 34322–34328 (2002).

  53. 53.

    Haldar, S. M. et al. Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc. Natl Acad. Sci. USA 109, 6739–6744 (2012).

  54. 54.

    Prosdocimo, D. A. et al. Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J. Biol. Chem. 289, 5914–5924 (2014).

  55. 55.

    Prosdocimo, D. A. et al. KLF15 and PPARalpha cooperate to regulate cardiomyocyte lipid gene expression and oxidation. PPAR Res 2015, 201625 (2015).

  56. 56.

    Oishi, Y. et al. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat. Med. 14, 656–666 (2008).

  57. 57.

    Liao, X. et al. Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J. Clin. Invest. 125, 3461–3476 (2015).

  58. 58.

    Cunningham, J. T. et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450, 736–740 (2007).

  59. 59.

    Blattler, S. M. et al. Defective mitochondrial morphology and bioenergetic function in mice lacking the transcription factor Yin Yang 1 in skeletal muscle. Mol. Cell. Biol. 32, 3333–3346 (2012).

  60. 60.

    Seth, A. et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 6, 236–245 (2007).

  61. 61.

    Chen, Y. et al. Roles of transcriptional corepressor RIP140 and coactivator PGC-1alpha in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes. Mol. Cell. Endocrinol. 362, 11–18 (2012).

  62. 62.

    Hasumi, H. et al. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J. Natl Cancer Inst. 104, 1750–1764 (2012).

  63. 63.

    Reyes, N. L. et al. Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. Proc. Natl Acad. Sci. USA 112, 424–429 (2015).

  64. 64.

    Liu, J. et al. Coupling of mitochondrial function and skeletal muscle fiber type by a miR-499/Fnip1/AMPK circuit. EMBO Mol. Med. 8, 1212–1228 (2016).

  65. 65.

    Schrepfer, E. & Scorrano, L. Mitofusins, from mitochondria to metabolism. Mol. Cell 61, 683–694 (2016).

  66. 66.

    Mishra, P., Varuzhanyan, G., Pham, A. H. & Chan, D. C. Mitochondrial dynamics is a distinguishing feature of skeletal muscle fiber types and regulates organellar compartmentalization. Cell Metab. 22, 1033–1044 (2015).

  67. 67.

    Sebastian, D. et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc. Natl Acad. Sci. USA 109, 5523–5528 (2012).

  68. 68.

    Sebastian, D. et al. Mfn2 deficiency links age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway. EMBO J. 35, 1677–1693 (2016).

  69. 69.

    de Brito, O. M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610 (2008).

  70. 70.

    Filadi, R. et al. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. Proc. Natl Acad. Sci. USA 112, E2174–E2181 (2015).

  71. 71.

    Filadi, R. et al. On the role of Mitofusin 2 in endoplasmic reticulum-mitochondria tethering. Proc. Natl Acad. Sci. USA 114, E2266–e2267 (2017).

  72. 72.

    Naon, D. et al. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. Proc. Natl Acad. Sci. USA 113, 11249–11254 (2016).

  73. 73.

    Naon, D. et al. Reply to Filadi et al.: Does Mitofusin 2 tether or separate endoplasmic reticulum and mitochondria? Proc. Natl Acad. Sci. USA 114, E2268–e2269 (2017).

  74. 74.

    Chen, H. et al. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141, 280–289 (2010).

  75. 75.

    Varanita, T. et al. The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage. Cell Metab. 21, 834–844 (2015).

  76. 76.

    Civiletto, G. et al. Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. Cell Metab. 21, 845–854 (2015).

  77. 77.

    Tezze, C. et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab. 25, 1374–1389.e1376 (2017).

  78. 78.

    Pereira, R. O. et al. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J. 36, 2126–2145 (2017).

  79. 79.

    Touvier, T. et al. Muscle-specific Drp1 overexpression impairs skeletal muscle growth via translational attenuation. Cell Death Dis. 6, e1663 (2015).

  80. 80.

    Quiros, P. M., Langer, T. & Lopez-Otin, C. New roles for mitochondrial proteases in health, ageing and disease. Nat. Rev. Mol. Cell Biol. 16, 345–359 (2015).

  81. 81.

    Strauss, K. A. et al. CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon protease. Am. J. Hum. Genet. 96, 121–135 (2015).

  82. 82.

    Jenkinson, E. M. et al. Perrault syndrome is caused by recessive mutations in CLPP, encoding a mitochondrial ATP-dependent chambered protease. Am. J. Hum. Genet. 92, 605–613 (2013).

  83. 83.

    Bota, D. A. & Davies, K. J. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat. Cell Biol. 4, 674–680 (2002).

  84. 84.

    Haynes, C. M., Petrova, K., Benedetti, C., Yang, Y. & Ron, D. ClpP mediates activation of a mitochondrial unfolded protein response in C. elegans. Dev. Cell 13, 467–480 (2007).

  85. 85.

    Zhao, Q. et al. A mitochondrial specific stress response in mammalian cells. EMBO J. 21, 4411–4419 (2002).

  86. 86.

    Wu, Y. et al. Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. Cell 158, 1415–1430 (2014).

  87. 87.

    Quiros, P. M. et al. ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. Cell Rep. 8, 542–556 (2014).

  88. 88.

    Gispert, S. et al. Loss of mitochondrial peptidase ClpP leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Hum. Mol. Genet. 22, 4871–4887 (2013).

  89. 89.

    Rugarli, E. I. & Langer, T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 31, 1336–1349 (2012).

  90. 90.

    Okamoto, K. Organellophagy: eliminating cellular building blocks via selective autophagy. J. Cell Biol. 205, 435–445 (2014).

  91. 91.

    Youle, R. J. & Narendra, D. P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9–14 (2011).

  92. 92.

    Liu, L., Sakakibara, K., Chen, Q. & Okamoto, K. Receptor-mediated mitophagy in yeast and mammalian systems. Cell Res. 24, 787–795 (2014).

  93. 93.

    Novak, I. et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 11, 45–51 (2010).

  94. 94.

    Liu, L. et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 14, 177–185 (2012).

  95. 95.

    Wei, Y., Chiang, W. C., Sumpter, R. Jr., Mishra, P. & Levine, B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell 168, 224–238.e210 (2017).

  96. 96.

    Chen, Y. & Dorn, G. W. 2nd PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471–475 (2013).

  97. 97.

    Chen, C. C. W., Erlich, A. T. & Hood, D. A. Role of Parkin and endurance training on mitochondrial turnover in skeletal muscle. Skelet. Muscle 8, 10 (2018).

  98. 98.

    Chen, G. et al. A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol. Cell 54, 362–377 (2014).

  99. 99.

    Fu, T. et al. Mitophagy directs muscle-adipose crosstalk to alleviate dietary obesity. Cell Rep. 23, 1357–1372 (2018).

  100. 100.

    He, C. et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481, 511–515 (2012).

  101. 101.

    Kim, K. H. et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19, 83–92 (2013).

  102. 102.

    Soriano, F. X. et al. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes 55, 1783–1791 (2006).

  103. 103.

    Martin, O. J. et al. A role for peroxisome proliferator-activated receptor gamma coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ. Res. 114, 626–636 (2014).

  104. 104.

    Vainshtein, A., Desjardins, E. M., Armani, A., Sandri, M. & Hood, D. A. PGC-1alpha modulates denervation-induced mitophagy in skeletal muscle. Skelet. Muscle 5, 9 (2015).

  105. 105.

    Vainshtein, A., Tryon, L. D., Pauly, M. & Hood, D. A. Role of PGC-1alpha during acute exercise-induced autophagy and mitophagy in skeletal muscle. Am. J. Physiol. Cell Physiol. 308, C710–C719 (2015).

  106. 106.

    Lee, J. M. et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516, 112–115 (2014).

  107. 107.

    Twig, G. et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27, 433–446 (2008).

  108. 108.

    Otera, H. & Mihara, K. Molecular mechanisms and physiologic functions of mitochondrial dynamics. J. Biochem 149, 241–251 (2011).

  109. 109.

    Gong, G. et al. Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice. Science 350, aad2459 (2015).

  110. 110.

    Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 144, 689–702 (2011).

  111. 111.

    Lee, Y. et al. PINK1 primes Parkin-mediated ubiquitination of PARIS in dopaminergic neuronal survival. Cell Rep. 18, 918–932 (2017).

  112. 112.

    Chen, C. C. W., Erlich, A. T., Crilly, M. J. & Hood, D. A. Parkin is required for exercise-induced mitophagy in muscle: impact of aging. Am. J. Physiol. Endocrinol. Metab. (2018). https://doi.org/10.1152/ajpendo.00391.2017.

  113. 113.

    Toyama, E. Q. et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281 (2016).

  114. 114.

    Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456–461 (2011).

  115. 115.

    Laker, R. C. et al. Ampk phosphorylation of Ulk1 is required for targeting of mitochondria to lysosomes in exercise-induced mitophagy. Nat. Commun. 8, 548 (2017).

  116. 116.

    O’Neill, H. M. et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc. Natl Acad. Sci. USA 108, 16092–16097 (2011).

  117. 117.

    Quiros, P. M., Mottis, A. & Auwerx, J. Mitonuclear communication in homeostasis and stress. Nat. Rev. Mol. Cell Biol. 17, 213–226 (2016).

  118. 118.

    Haynes, C. M. & Ron, D. The mitochondrial UPR - protecting organelle protein homeostasis. J. Cell Sci. 123, 3849–3855 (2010).

  119. 119.

    Yoneda, T. et al. Compartment-specific perturbation of protein handling activates genes encoding mitochondrial chaperones. J. Cell Sci. 117, 4055–4066 (2004).

  120. 120.

    Nargund, A. M., Pellegrino, M. W., Fiorese, C. J., Baker, B. M. & Haynes, C. M. Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. Science 337, 587–590 (2012).

  121. 121.

    Shpilka, T. & Haynes, C. M. The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. Nat. Rev. Mol. Cell Biol. 19, 109–120 (2018).

  122. 122.

    Durieux, J., Wolff, S. & Dillin, A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 144, 79–91 (2011).

  123. 123.

    Matilainen, O., Quiros, P. M. & Auwerx, J. Mitochondria and epigenetics - crosstalk in homeostasis and stress. Trends Cell Biol. 27, 453–463 (2017).

  124. 124.

    Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).

  125. 125.

    McDonnell, E. et al. Lipids reprogram metabolism to become a major carbon source for histone acetylation. Cell Rep. 17, 1463–1472 (2016).

  126. 126.

    Chiang, P. K. et al. S-adenosylmethionine and methylation. FASEB J. 10, 471–480 (1996).

  127. 127.

    Lowell, B. B. & Shulman, G. I. Mitochondrial dysfunction and type 2 diabetes. Science 307, 384–387 (2005).

  128. 128.

    Szendroedi, J., Phielix, E. & Roden, M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 92–103 (2011).

  129. 129.

    Muoio, D. M. & Neufer, P. D. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab. 15, 595–605 (2012).

  130. 130.

    Samuel, V. T. & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012).

  131. 131.

    Pospisilik, J. A. et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 131, 476–491 (2007).

  132. 132.

    Wredenberg, A. et al. Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem. Biophys. Res. Commun. 350, 202–207 (2006).

  133. 133.

    Rattan, S. I. Hormesis in aging. Ageing Res. Rev. 7, 63–78 (2008).

  134. 134.

    Yun, J. & Finkel, T. Mitohormesis. Cell Metab. 19, 757–766 (2014).

  135. 135.

    Chung, H. K. et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J. Cell Biol. 216, 149–165 (2017).

  136. 136.

    Lee, C. et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 21, 443–454 (2015).

  137. 137.

    Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635 (2005).

  138. 138.

    Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415–425 (2007).

  139. 139.

    Owen, B. M. et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20, 670–677 (2014).

  140. 140.

    Suomalainen, A. et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 10, 806–818 (2011).

  141. 141.

    Tyynismaa, H. et al. Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 19, 3948–3958 (2010).

  142. 142.

    Jay, V. & Vajsar, J. The dystrophy of Duchenne. Lancet 357, 550–552 (2001).

  143. 143.

    Bulfield, G., Siller, W. G., Wight, P. A. & Moore, K. J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA 81, 1189–1192 (1984).

  144. 144.

    Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T. & Magyar, J. P. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord. 14, 675–682 (2004).

  145. 145.

    Webster, C., Silberstein, L., Hays, A. P. & Blau, H. M. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52, 503–513 (1988).

  146. 146.

    Kuznetsov, A. V. et al. Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol. Cell. Biochem. 183, 87–96 (1998).

  147. 147.

    Timmons, J. A. et al. Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. FASEB J. 19, 750–760 (2005).

  148. 148.

    Handschin, C. et al. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 21, 770–783 (2007).

  149. 149.

    Selsby, J. T., Morine, K. J., Pendrak, K., Barton, E. R. & Sweeney, H. L. Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE 7, e30063 (2012).

  150. 150.

    Ljubicic, V., Burt, M., Lunde, J. A. & Jasmin, B. J. Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1alpha axis. Am. J. Physiol. Cell Physiol. 307, C66–C82 (2014).

  151. 151.

    Ljubicic, V. et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum. Mol. Genet. 20, 3478–3493 (2011).

  152. 152.

    Chalkiadaki, A., Igarashi, M., Nasamu, A. S., Knezevic, J. & Guarente, L. Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of Duchenne muscular dystrophy. PLoS Genet. 10, e1004490 (2014).

  153. 153.

    Pauly, M. et al. AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am. J. Pathol. 181, 583–592 (2012).

  154. 154.

    De Palma, C. et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis. 3, e418 (2012).

  155. 155.

    Egerman, M. A. & Glass, D. J. Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 49, 59–68 (2014).

  156. 156.

    Wall, B. T., Dirks, M. L. & van Loon, L. J. Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. Ageing Res. Rev. 12, 898–906 (2013).

  157. 157.

    Hvid, L. G. et al. Four days of muscle disuse impairs single fiber contractile function in young and old healthy men. Exp. Gerontol. 48, 154–161 (2013).

  158. 158.

    Paddon-Jones, D. et al. Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. J. Clin. Endocrinol. Metab. 89, 4351–4358 (2004).

  159. 159.

    Suetta, C. et al. Effects of aging on human skeletal muscle after immobilization and retraining. J. Appl. Physiol. (1985) 107, 1172–1180 (2009).

  160. 160.

    Hvid, L. G. et al. Aging impairs the recovery in mechanical muscle function following 4 days of disuse. Exp. Gerontol. 52, 1–8 (2014).

  161. 161.

    Dirks, M. L. et al. One week of bed rest leads to substantial muscle atrophy and induces whole-body insulin resistance in the absence of skeletal muscle lipid accumulation. Diabetes 65, 2862–2875 (2016).

  162. 162.

    Suetta, C. et al. Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS ONE 7, e51238 (2012).

  163. 163.

    Brocca, L. et al. The time course of the adaptations of human muscle proteome to bed rest and the underlying mechanisms. J. Physiol. 590, 5211–5230 (2012).

  164. 164.

    Feng, H. Z., Chen, X., Malek, M. H. & Jin, J. P. Slow recovery of the impaired fatigue resistance in postunloading mouse soleus muscle corresponding to decreased mitochondrial function and a compensatory increase in type I slow fibers. Am. J. Physiol. Cell Physiol. 310, C27–C40 (2016).

  165. 165.

    Sandri, M. et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl Acad. Sci. USA 103, 16260–16265 (2006).

  166. 166.

    Geng, T., Li, P., Yin, X. & Yan, Z. PGC-1alpha promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. Am. J. Pathol. 178, 1738–1748 (2011).

  167. 167.

    Cannavino, J., Brocca, L., Sandri, M., Bottinelli, R. & Pellegrino, M. A. PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592, 4575–4589 (2014).

  168. 168.

    Brault, J. J., Jespersen, J. G. & Goldberg, A. L. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010).

  169. 169.

    Kang, C., Goodman, C. A., Hornberger, T. A. & Ji, L. L. PGC-1alpha overexpression by in vivo transfection attenuates mitochondrial deterioration of skeletal muscle caused by immobilization. FASEB J. 29, 4092–4106 (2015).

  170. 170.

    Tonkonogi, M. et al. Reduced oxidative power but unchanged antioxidative capacity in skeletal muscle from aged humans. Pflugers Arch. 446, 261–269 (2003).

  171. 171.

    Conley, K. E. et al. Ageing, muscle properties and maximal O(2) uptake rate in humans. J. Physiol. 526(Pt 1), 211–217 (2000).

  172. 172.

    Short, K. R. et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc. Natl Acad. Sci. USA 102, 5618–5623 (2005).

  173. 173.

    Chabi, B. et al. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell 7, 2–12 (2008).

  174. 174.

    Safdar, A. et al. Aberrant mitochondrial homeostasis in the skeletal muscle of sedentary older adults. PLoS ONE 5, e10778 (2010).

  175. 175.

    Joseph, A. M. et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell 11, 801–809 (2012).

  176. 176.

    Santanasto, A. J. et al. Skeletal muscle mitochondrial function and fatigability in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 70, 1379–1385 (2015).

  177. 177.

    Coen, P. M. et al. Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 68, 447–455 (2013).

  178. 178.

    Santanasto, A. J. et al. The relationship between mitochondrial function and walking performance in older adults with a wide range of physical function. Exp. Gerontol. 81, 1–7 (2016).

  179. 179.

    Lourenco dos Santos, S. et al. Oxidative proteome alterations during skeletal muscle ageing. Redox Biol. 5, 267–274 (2015).

  180. 180.

    Joseph, A. M. et al. Dysregulation of mitochondrial quality control processes contribute to sarcopenia in a mouse model of premature aging. PLoS ONE 8, e69327 (2013).

  181. 181.

    Carnio, S. et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 8, 1509–1521 (2014).

  182. 182.

    Gouspillou, G. et al. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans. FASEB J. 28, 1621–1633 (2014).

  183. 183.

    Masiero, E. et al. Autophagy is required to maintain muscle mass. Cell Metab. 10, 507–515 (2009).

  184. 184.

    Canto, C. et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012).

  185. 185.

    Ryu, D. et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med. 8, 361ra139 (2016).

  186. 186.

    van de Weijer, T. et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes 64, 1193–1201 (2015).

Download references

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 31471110, 31771291); the Ministry of Science and Technology of China (973 Program 2015CB856300); Natural Science Foundation of Jiangsu Province (BK20170014); and Fundamental Research Funds for the Central Universities (090314380023) to Z.G. and NIH grants R01 DK045416, R01 HL058493, and R01 HL128349 to D.P.K.

Author information

Affiliations

  1. The State Key Laboratory of Pharmaceutical Biotechnology and MOE Key Laboratory of Model Animals for Disease Study, Department of Spine Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Model Animal Research Center of Nanjing University, 210061, Nanjing, China

    • Zhenji Gan
    •  & Tingting Fu
  2. Cardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    • Daniel P. Kelly
  3. Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, FL, 32804, USA

    • Rick B. Vega

Authors

  1. Search for Zhenji Gan in:

  2. Search for Tingting Fu in:

  3. Search for Daniel P. Kelly in:

  4. Search for Rick B. Vega in:

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Zhenji Gan or Daniel P. Kelly or Rick B. Vega.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41422-018-0078-7